Silverarc Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Silverarc Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-39,733	Closed	-$403K	–	74
2024 Q4	$403K	Buy	39,733 +2,502	+7%	+$30.3K	0.09%	58
2024 Q3	$464K	Hold	37,231	–	–	0.1%	64
2024 Q2	$485K	Hold	37,231	–	–	0.11%	65
2024 Q1	$843K	Sell	37,231 -233	-0.6%	-$4.08K	0.23%	62
2023 Q4	$486K	Hold	37,464	–	–	0.14%	63
2023 Q3	$753K	Buy	37,464 +2,865	+8%	+$64.3K	0.23%	65
2023 Q2	$929K	Sell	34,599 -68,163	-66%	-$2.94M	0.29%	59
2023 Q1	$6M	Buy	+102,762	New	+$5.07M	2.48%	14

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Silverarc Capital Management's KPTI Position: Q1 2025 in Review

Silverarc Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 39,733 shares — an estimated $403K sold.

Silverarc Capital Management first reported a position in KPTI in Q1 2023 and held it in 8 quarters. The position peaked at $6M in Q1 2023. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

Silverarc Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
Silverarc Capital Management sold 39,733 Karyopharm Therapeutics shares in Q1 2025, an estimated $403K.
Silverarc Capital Management first reported a position in Karyopharm Therapeutics in Q1 2023 and held it in 8 quarters.
Silverarc Capital Management's Karyopharm Therapeutics position peaked at $6M in Q1 2023.
49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.